Canada Study: Closed-Loop Insulin Pumps After Pregnancy

A Study from Canada Sheds Light on "Artificial Pancreas" Tech for New Moms With Type 1 Diabetes

A study from Canada is offering valuable real-world insight into how closed-loop insulin delivery systems — sometimes called an "artificial pancreas" — perform during one of the most demanding periods in a diabetic woman's life: the weeks and months after giving birth.

Researchers at the University of Alberta in Edmonton conducted in-depth interviews with 16 women living with Type 1 diabetes and their partners, examining their experiences with the MiniMed 670G or 770G (Medtronic) hybrid closed-loop system during the first 24 weeks after delivery. Their findings, published in the Canadian Journal of Diabetes (2024), reveal both the promise and the frustrations of this emerging technology.

What Is a Closed-Loop System?

A hybrid closed-loop insulin delivery system automatically adjusts insulin doses in real time based on continuous glucose monitor (CGM) readings. It's designed to reduce the constant mental workload of diabetes management — something that becomes especially burdensome when you're also caring for a newborn.

What the Canadian Researchers Found

• Fewer dangerous lows: Participants reported spending significantly less time in hypoglycemia (low blood sugar, below 70 mg/dL) compared to their previous experience with manual insulin delivery. Sleep deprivation and unpredictable newborn feeding schedules make hypoglycemia a serious postpartum risk, so this was a meaningful benefit.
• Running higher than desired: On the flip side, many women were frustrated that the system sometimes allowed blood glucose to drift higher than they personally wanted — often above 180 mg/dL (the standard postpartum target in both Canadian and US guidelines).
• Infant feeding wasn't affected — but it affected diabetes: The closed-loop system did not change whether mothers chose to breastfeed, but breastfeeding and newborn care routines did complicate diabetes management regardless of the device used.
• Partners felt uncertain: Spouses and partners — many of whom had watched their loved ones master intensive manual diabetes management — expressed unease about "handing over control" to an algorithm.
• Users wanted to understand the algorithm better: Participants frequently expressed a desire for clearer explanations of how the system made decisions, suggesting a gap in education and onboarding.

Why This Matters for US Patients

The MiniMed 670G and 770G systems studied in Canada are FDA-approved and widely used in the United States, making these findings directly applicable to American patients. The American Diabetes Association (ADA) recommends that pregnant and postpartum women with Type 1 diabetes aim for blood glucose levels between 70–180 mg/dL, with a target A1C below 7%. Closed-loop technology can be a powerful tool in meeting those goals — but as this Canadian research shows, it's not a hands-free solution.

For US patients considering closed-loop systems after delivery, this study offers a realistic preview: expect fewer scary lows, but plan to work closely with your endocrinologist to fine-tune glucose targets. Make sure your care team walks you — and your partner — through exactly how the algorithm works before you bring your baby home.

The Bottom Line

Closed-loop insulin delivery offers real relief for new mothers with Type 1 diabetes, particularly by reducing hypoglycemia risk. But technology alone isn't enough — patient education, partner support, and personalized glucose targets remain essential pieces of the puzzle.

Source: Quintanilha, Yamamoto, Aylward. "Women's and Partners' Experiences With a Closed-loop Insulin Delivery System to Manage Type 1 Diabetes in the Postpartum Period." Canadian Journal of Diabetes, 2024. PMID: 39236999. DOI: 10.1016/j.jcjd.2024.08.005